Shares of Fresenius Medical Care AG (NYSE:FMS) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $45.89 and last traded at $45.65, with a volume of 74,386 shares changing hands. The stock had previously closed at $45.65.

FMS has been the subject of several recent research reports. Jefferies Group upgraded Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a research note on Friday, July 8th. Sanford C. Bernstein initiated coverage on Fresenius Medical Care AG in a research note on Monday, April 11th. They issued an “outperform” rating for the company. Royal Bank Of Canada restated a “hold” rating on shares of Fresenius Medical Care AG in a research note on Tuesday, May 24th. Zacks Investment Research upgraded Fresenius Medical Care AG from a “sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, DZ Bank AG reiterated a “sell” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, May 10th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $42.50.

The firm has a market capitalization of $28.20 billion and a price-to-earnings ratio of 26.87. The firm has a 50 day moving average of $43.36 and a 200 day moving average of $43.06.

Fresenius Medical Care AG (NYSE:FMS) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported $0.96 EPS for the quarter, beating the Zacks’ consensus estimate of $0.92 by $0.04. The business had revenue of $4.42 billion for the quarter, compared to analysts’ expectations of $4.54 billion. Analysts predict that Fresenius Medical Care AG will post $2.03 earnings per share for the current year.

Several hedge funds have modified their holdings of FMS. Morgan Stanley increased its stake in shares of Fresenius Medical Care AG by 20.5% in the fourth quarter. Morgan Stanley now owns 685,338 shares of the company’s stock worth $28,675,000 after buying an additional 116,653 shares during the last quarter. US Bancorp DE increased its stake in Fresenius Medical Care AG by 4.0% in the fourth quarter. US Bancorp DE now owns 274,935 shares of the company’s stock worth $11,503,000 after buying an additional 10,479 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Fresenius Medical Care AG by 3.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 107,376 shares of the company’s stock worth $4,493,000 after buying an additional 3,694 shares in the last quarter. Bank of Montreal Can increased its stake in Fresenius Medical Care AG by 60.0% in the fourth quarter. Bank of Montreal Can now owns 56,700 shares of the company’s stock worth $2,373,000 after buying an additional 21,264 shares in the last quarter. Finally, WBI Investments Inc. purchased a new stake in Fresenius Medical Care AG during the fourth quarter worth about $2,249,000.

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.